CDX
LNCaP clone FGC
Tumor indication
Prostate
Tumor subtype
Prostate Carcinoma (derived from lymph node)
Description
LNCaP clone FGC (Prostate Cancer CDX Model)
The LNCaP clone FGC line was derived from a lymph node metastasis of human prostate carcinoma. It is androgen-sensitive, expressing functional androgen receptors. LNCaP cells also produce prostate-specific antigen (PSA), aligning with clinical biomarkers. This makes it a valuable model for early and androgen-responsive prostate cancer research.
Key Features:
- Derived from lymph node metastasis of prostate cancer.
- Androgen receptor–positive.
- Produces PSA.
- Useful in hormone-dependent prostate cancer studies.
Applications:
LNCaP is applied in studies of androgen receptor biology and therapeutic response. It supports biomarker validation, including PSA monitoring. Researchers use it to evaluate anti-androgen and hormonal therapies. Its androgen sensitivity makes it highly relevant for translational prostate cancer pipelines.
Details
- Tumor indication
- Prostate
- Tumor subtype
- Prostate Carcinoma (derived from lymph node)
- Organism
- Human
- Mouse sex
- Male
- Lumin data
- RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.